PE firm invests in growing eClinical solutions company

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Jirupong Manustrong)
(Image: Getty/ Jirupong Manustrong)

Related tags: Private equity, Private equity firm, eclinical, CTMS, Data management, Clinical trials, Clinical research

eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase service offerings for Phase I-III clinical trials.

Toronto-based Axiom specializes in electronic data capture (EDC), data management, clinical trial management systems (CTMS), and electronic patient reported outcomes (ePRO) for biotechnology and pharmaceutical sponsors conducting clinical trials.

According to Noah Rhodes, managing director at Great Point Partners, Axiom has been growing at 56% per year over the last six years.

Green Point Partners, which has invested in the clinical trial service industry prior to this recapitalization, approached Axiom regarding the partnership.

While financial details of this recapitalization have not been disclosed, Andrew Schacter, founder and CEO of Axiom said in a statement that, “GPP’s investment will allow Axiom to increase the level of customer service and add additional technology solutions and services.”

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more